This recombinant monoclonal antibody is designed as a research-grade biosimilar to ES-004, targeting Signal Regulatory Protein Alpha (SIRPA, also known as CD172a or SHPS-1). SIRPA is an inhibitory receptor expressed primarily on myeloid cells, including macrophages, dendritic cells, and neutrophils, where it plays a critical role in regulating innate immune responses. Upon binding to its ligand CD47, SIRPA transmits a "don't eat me" signal that inhibits phagocytosis, allowing cells to evade immune surveillance. This mechanism is frequently exploited by cancer cells that overexpress CD47, making the SIRPA-CD47 axis an important therapeutic target in immuno-oncology. Dysregulation of SIRPA signaling has been implicated in various malignancies, autoimmune disorders, and inflammatory conditions.
ES-004 is an Fc-engineered monoclonal antibody targeting the αV1 domain of SIRPA. It is currently in clinical Phase I/II and is being evaluated for its safety, tolerability and preliminary efficacy in the treatment of advanced solid tumors. This biosimilar antibody provides researchers with a reliable tool for studying SIRPA biology, exploring checkpoint blockade mechanisms, and developing novel therapeutic approaches targeting the innate immune system in oncology and immunology research.
Email: support@cusabio.com
Distributors Worldwide